SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)

In XLH, excess circulating FGF23 causes hypophosphatemia, rickets, lower limb deformity, and impaired growth and mobility. An active-controlled, phase 3 trial (CL301; NCT02915705) showed treatment with burosumab, a fully human monoclonal antibody against FGF23, resulted in significantly greater impr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Endocr Soc
Main Authors: Imel, Erik A, Chen, Angel, Chang, Ting, Roberts, Mary Scott, Ward, Leanne Marie
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Bone and Mineral Metabolism
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208884/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.196
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki